132 related articles for article (PubMed ID: 11825112)
1. A103 immunostaining in the diagnosis of adrenal cortical tumors: an immunohistochemical study of 316 cases.
Loy TS; Phillips RW; Linder CL
Arch Pathol Lab Med; 2002 Feb; 126(2):170-2. PubMed ID: 11825112
[TBL] [Abstract][Full Text] [Related]
2. [Diagnostic value of A103 and inhibin-alpha in adrenocortical tumors: an immunohistochemical study using tissue microarray techniques].
Zhang HY; Wang XJ; Liu WP; Jiang LL; Li GD; Guo J; Zhang YH
Zhonghua Bing Li Xue Za Zhi; 2004 Jun; 33(3):203-7. PubMed ID: 15256108
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic utility of the monoclonal antibody A103 in fine-needle aspiration biopsies of the adrenal.
Shin SJ; Hoda RS; Ying L; DeLellis RA
Am J Clin Pathol; 2000 Feb; 113(2):295-302. PubMed ID: 10664633
[TBL] [Abstract][Full Text] [Related]
4. A comparison of A103 and inhibin reactivity in adrenal cortical tumors: distinction from hepatocellular carcinoma and renal tumors.
Renshaw AA; Granter SR
Mod Pathol; 1998 Dec; 11(12):1160-4. PubMed ID: 9872645
[TBL] [Abstract][Full Text] [Related]
5. Melan A (A103) is expressed in adrenocortical neoplasms but not in renal cell and hepatocellular carcinomas.
Ghorab Z; Jorda M; Ganjei P; Nadji M
Appl Immunohistochem Mol Morphol; 2003 Dec; 11(4):330-3. PubMed ID: 14663359
[TBL] [Abstract][Full Text] [Related]
6. A103: An anti-melan-a monoclonal antibody for the detection of malignant melanoma in paraffin-embedded tissues.
Jungbluth AA; Busam KJ; Gerald WL; Stockert E; Coplan KA; Iversen K; MacGregor DP; Old LJ; Chen YT
Am J Surg Pathol; 1998 May; 22(5):595-602. PubMed ID: 9591730
[TBL] [Abstract][Full Text] [Related]
7. Melan-A (A103) and inhibin expression in ovarian neoplasms.
Yao DX; Soslow RA; Hedvat CV; Leitao M; Baergen RN
Appl Immunohistochem Mol Morphol; 2003 Sep; 11(3):244-9. PubMed ID: 12966351
[TBL] [Abstract][Full Text] [Related]
8. Immunoreactivity for A103, an antibody to melan-A (Mart-1), in adrenocortical and other steroid tumors.
Busam KJ; Iversen K; Coplan KA; Old LJ; Stockert E; Chen YT; McGregor D; Jungbluth A
Am J Surg Pathol; 1998 Jan; 22(1):57-63. PubMed ID: 9422316
[TBL] [Abstract][Full Text] [Related]
9. Immunoreactivity of A103, an antibody to Melan A, in canine steroid-producing tissues and their tumors.
Ramos-Vara JA; Beissenherz ME; Miller MA; Johnson GC; Kreeger JM; Pace LW; Turk JR; Turnquist SE; Watson GL; Yamini B
J Vet Diagn Invest; 2001 Jul; 13(4):328-32. PubMed ID: 11478605
[TBL] [Abstract][Full Text] [Related]
10. The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: a comparison of the novel T311 antibody (anti-tyrosinase) with S-100, HMB45, and A103 (anti-melan-A).
Clarkson KS; Sturdgess IC; Molyneux AJ
J Clin Pathol; 2001 Mar; 54(3):196-200. PubMed ID: 11253130
[TBL] [Abstract][Full Text] [Related]
11. [The expression of A103 and inhibin alpha in adrenocortical adenoma by high-throughput tissue microarray techniques].
Zhang H; Liu W; Wang X; Li G; Guo J; Li F; Liao D
Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Jul; 34(3):424-6. PubMed ID: 12910679
[TBL] [Abstract][Full Text] [Related]
12. Melan A/MART-1 immunoreactivity in formalin-fixed paraffin-embedded primary and metastatic melanoma: frequency and distribution.
Hofbauer GF; Kamarashev J; Geertsen R; Böni R; Dummer R
Melanoma Res; 1998 Aug; 8(4):337-43. PubMed ID: 9764809
[TBL] [Abstract][Full Text] [Related]
13. Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma.
Busam KJ; Chen YT; Old LJ; Stockert E; Iversen K; Coplan KA; Rosai J; Barnhill RL; Jungbluth AA
Am J Surg Pathol; 1998 Aug; 22(8):976-82. PubMed ID: 9706977
[TBL] [Abstract][Full Text] [Related]
14. The role of calretinin, inhibin, melan-A, BCL-2, and C-kit in differentiating adrenal cortical and medullary tumors: an immunohistochemical study.
Zhang PJ; Genega EM; Tomaszewski JE; Pasha TL; LiVolsi VA
Mod Pathol; 2003 Jun; 16(6):591-7. PubMed ID: 12808065
[TBL] [Abstract][Full Text] [Related]
15. Melan-A, a new melanocytic differentiation marker.
Busam KJ; Jungbluth AA
Adv Anat Pathol; 1999 Jan; 6(1):12-8. PubMed ID: 10197235
[TBL] [Abstract][Full Text] [Related]
16. Differential expression of MART-1, tyrosinase, and SM5-1 in primary and metastatic melanoma.
Reinke S; Königer P; Herberth G; Audring H; Wang H; Ma J; Guo Y; Sterry W; Trefzer U
Am J Dermatopathol; 2005 Oct; 27(5):401-6. PubMed ID: 16148409
[TBL] [Abstract][Full Text] [Related]
17. Comparison of immunohistochemical markers in the differential diagnosis of adrenocortical tumors: immunohistochemical analysis of adrenocortical tumors.
Zhang H; Bu H; Chen H; Wei B; Liu W; Guo J; Li F; Liao D; Tang Y; Zhang Z
Appl Immunohistochem Mol Morphol; 2008 Jan; 16(1):32-9. PubMed ID: 18091323
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical investigation of PNL2 reactivity of canine melanocytic neoplasms and comparison with Melan A.
Giudice C; Ceciliani F; Rondena M; Stefanello D; Grieco V
J Vet Diagn Invest; 2010 May; 22(3):389-94. PubMed ID: 20453212
[TBL] [Abstract][Full Text] [Related]
19. Melan A (A103) is not a marker of mesothelioma.
Ordóñez NG; Shen SS; Zenali M; Deavers MT
Appl Immunohistochem Mol Morphol; 2013 Mar; 21(2):181-4. PubMed ID: 22820661
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical staining of normal, hyperplastic, and neoplastic adrenal cortex with a monoclonal antibody against alpha inhibin.
McCluggage WG; Burton J; Maxwell P; Sloan JM
J Clin Pathol; 1998 Feb; 51(2):114-6. PubMed ID: 9602683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
